<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497754</url>
  </required_header>
  <id_info>
    <org_study_id>NL62664.091.17</org_study_id>
    <nct_id>NCT03497754</nct_id>
  </id_info>
  <brief_title>The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients</brief_title>
  <acronym>Soundprobe</acronym>
  <official_title>The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients, a Feasibility Study. (the Soundprobe Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the feasibility of an external ultrasound fixator (ProbeFix)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Study to assess the feasibility of an external ultrasound fixator (ProbeFix)
      Objective: Cardiac output measurements using transthoracic ultrasound (TTE) with and without
      the use of the probeFixR will be evaluated in terms of accuracy. The TTE measurements will be
      combined with another form of cardiac output measurements (FlotracR) after a passive leg
      rasing (PLR) test.

      Study design prospective, feasibility study Study population: Adult Intensive Care patients (
      &gt; 18 years)

      Intervention (if applicable):

      Consecutive adult patients on the ICU in which the FlotracR monitor is used will be evaluated
      after detection of hypovolemia.

      Main study parameters/endpoints:

        -  Percentage of patients in which the ProbeFixR can be used

        -  The correlation between the measurements done by FlotracR and TTE with and TTE without
           ProbeFixR

      Although no side effects are to be expected the investigators will monitor the patients after
      the ProbeFix is removed for any skin damage. The investigators will grade this damage into 3
      categories:

        -  No skin marks

        -  Mild skin marks (no treatment necessary)

        -  Severe skin marks (surgical or medical treatment necessary)

        -  If the patients are awake the investigators will ask them whether they felt the
           ProbeFixR to be unpleasant on a scale of 0-10 (0 being: I did not feel anything and 10
           being very unpleasant).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">April 23, 2019</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR</measure>
    <time_frame>8 weeks</time_frame>
    <description>A Bland and Altman plot will be constructed and the limits of agreement will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin marks as possible side effect; scored as 'no skin marks', 'mild skin marks (no treatment necessary)' or 'severe skin marks (surgical or medical treatment necessary)'</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentages will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is the Probefix unpleasant on a scale of 0-10</measure>
    <time_frame>8 weeks</time_frame>
    <description>The VAS scale will be reported as mean with standard deviation if normally distributed or as median and inter-quartile range if not normally distributed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients in which the ProbeFixR can be used</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentages will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>Cardiac output measurements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Probefix</intervention_name>
    <description>A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.</description>
    <arm_group_label>Cardiac output measurements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Intensive Care patients ( &gt; 18 years), with hypovolemia detected with Flotrac
             (SVV &gt; 10%)

        Exclusion Criteria:

          -  Pregnancy

          -  Atrial fibrillation or other irregular heart rhythm

          -  Pulmonary edema

          -  PLR not possible (eg neurological disease, spinal trauma, restricted limb movement,
             deep venous thrombosis, or any other reason as indicated by the attending
             intensivist).

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bianca Baten, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ultrasound</keyword>
  <keyword>cardiac output</keyword>
  <keyword>Probefix</keyword>
  <keyword>passive leg raising test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

